PRIME Oncology featured event

Washington, D.C. Saturday, January 24, 2009	Houston, Texas Saturday, January 31, 2009
New York, New York Saturday, February 7, 2009	Atlanta, Georgia Saturday, February 21, 2009

Registration is required for this event.

This unique series of four live, one day meetings will provide expert reviews of the most meaningful and practice changing data in the field of hematologic malignancies presented at ASH and other major society meetings held throughout 2008. In addition to didactic lectures, the format of the meeting also includes interactive “The Smartest Oncologist/Hematologist Quizzes”.

Who Should Attend
This educational activity is intended for oncologists, hematologists, physicians, internists, and other healthcare professionals interested in the management of hematologic malignancies.

Statement of Need
As the rate at which clinical data is released increases and the numbers of therapeutic options grow, it is important for practicing oncologists and hematologists to stay abreast of these advances. Many community oncologists, hematologists and other physicians involved in the management of hematologic malignancies do not attend major society meetings and likewise those who do, find the size and scope to be so broad and intensive that they require summaries of important data for ease of application to their daily practices. In order for rapid clinical progress to have a direct and immediate impact on patients’ lives, the newest findings must be readily applied by the practices of community oncologists. In addition, the data presented at large clinical conferences is typically not framed in the context of the clinical practices of the community oncologists. PRIME Oncology presents “Hematologic Malignancies Demystified: The Series” A Critical Appraisal of Data from 2008 and ASH, to review, summarize, and interpret the most clinically significant data in an effort to meet this need.

Educational Objectives
Upon completion of this educational activity, participants should be better able to:

• Describe the latest management approaches for hematologic malignancies including leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes and myeloproliferative disorders
• Explain difficult or unusual problems encountered by the practicing hematologist/oncologist
• Identify appropriate management options based on emerging data
• Discuss issues surrounding the design and conduct of clinical trials that incorporate novel agents and/or regimens for patients with hematologic malignancies
• Summarize emerging data in the management of multiple hematologic malignancies
• Integrate new findings into clinical practice